Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Oncobiologics ONSI.W

Healthcare Biotechnology

Recent & Breaking News (NDAQ:ONSI.W)

Outlook Therapeutics Announces $16.0 Million Private Placement to Advance the Development of ONS-5010 / LYTENAVA(TM) (bevacizumab-vikg)

GlobeNewswire May 26, 2020

Outlook Therapeutics Reports Financial Results for the Second Quarter of Fiscal Year 2020 and Provides Corporate Update

GlobeNewswire May 15, 2020

Outlook Therapeutics Bolsters Clinical and Commercial Expertise with Two Key Appointments to Board of Directors

GlobeNewswire April 21, 2020

Outlook Therapeutics to Present at the April 2020 Virtual Investor Summit

GlobeNewswire April 15, 2020

Outlook Therapeutics Provides COVID-19 Impact Update on Ongoing Clinical Trials NORSE 1 and NORSE 2

GlobeNewswire April 14, 2020

Outlook Therapeutics Announces LYTENAVA(TM) (bevacizumab-vikg), Anticipated Brand Name for ONS-5010, If Approved

GlobeNewswire March 5, 2020

Outlook Therapeutics Announces Closing of $10.2 Million Financings Priced At-The-Market

GlobeNewswire February 26, 2020

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Outlook Therapeutics, Inc.-OTLK

ACCESSWIRE IA February 25, 2020

Outlook Therapeutics Announces $10.2 Million Financings Priced At-The-Market

GlobeNewswire February 24, 2020

INVESTOR ALERT: Fields Kupka & Shukurov LLP Is Investigating Outlook Therapeutics, Inc. for Potential Securities Violations and Breach of Fiduciary Duty Claims.

GlobeNewswire February 18, 2020

Outlook Therapeutics Provides Business Update and Reports Financial Results for the First Quarter of Fiscal Year 2020

GlobeNewswire February 14, 2020

Outlook Therapeutics to Present at the 2020 BIO CEO & Investor Conference

GlobeNewswire February 4, 2020

Outlook Therapeutics Announces Agreements to Streamline Capital Structure and Regain 100% Ownership of Any Future Net Profits for ONS-5010

GlobeNewswire January 28, 2020

Outlook Therapeutics Announces Completion of Warrant Restructuring

GlobeNewswire December 26, 2019

Outlook Therapeutics Announces Warrant Amendment and Restructuring of Senior Secured Notes in Separate Transactions

GlobeNewswire December 23, 2019

Outlook Therapeutics Provides Business Update and Reports Financial Results for Fiscal Year 2019

GlobeNewswire December 19, 2019

Outlook Therapeutics Receives FDA Agreement for Three Special Protocol Assessments for Additional Planned Clinical Trials of ONS-5010

GlobeNewswire December 3, 2019

Outlook Therapeutics to Present at the 29th Annual Ladenburg Thalmann 2019 Healthcare Conference

GlobeNewswire September 11, 2019

Outlook Therapeutics to Present at the H.C. Wainwright 21st Annual Healthcare Conference

GlobeNewswire August 27, 2019

Outlook Therapeutics Completes Patient Enrollment for NORSE 1 a Phase 3 Clinical Trial for ONS-5010 in Wet AMD

GlobeNewswire August 20, 2019